glp-1 treatment milwaukee Agonists: Revolutionizing the of Obesity, but Are They Enough? - Eric Velazquez, MD - Bariatric Surgeon - Longstreet Clinic Center for Weight Management Health organization guidelines for drugs

Do not use Saxenda (liraglutide) if you or any of your family have ever had MTC, or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Prior to this several other anti-obesity drugs had also proven disappointing due to adverse effects such as cardiovascular problems, increased suicidal risk and enhanced drug dependence and abuse (Mller, Blher, Tschp, DiMarchi)

[DOI] [PMC free article] [PubMed] [Google Scholar] 86.Kaur C, Ling EA

Katada, S., Yanagimoto, A., Matsui, Y., Hibi, M., Osaki, N., Kobayashi, S., & Katsuragi, Y

Q1 2025: Novo Nordisk completes acquisition of Catalent for $16.5 billion to secure GLP-1 drug supply chain Novo Nordisk finalized its $16.5 billion acquisition of contract manufacturer Catalent, aiming to strengthen its supply chain and manufacturing capabilities for GLP-1-based medicines